| Literature DB >> 35118791 |
David Mondaca-Ruff1, Clara Quiroga2, Ignacio Norambuena-Soto1, Jaime A Riquelme1, Alejandra San Martin3, Mario Bustamante1,2, Sergio Lavandero1,4,5, Mario Chiong1.
Abstract
Hypertension is associated with high circulating angiotensin II (Ang II). We have reported that autophagy regulates Ang II-induced vascular smooth muscle cell (VSMC) hypertrophy, but the mechanism mediating this effect is still unknown. Therefore, we studied how Ang II regulates LC3 levels in VSMCs and whether Bag3, a co-chaperone known to regulate LC3 total levels, may be involved in the effects elicited by Ang II. A7r5 cell line or rat aortic smooth muscle cell (RASMC) primary culture were stimulated with Ang II 100 nM for 24 h and LC3 I, LC3 II and Bag3 protein levels were determined by Western blot. MAP1LC3B mRNA levels were assessed by RT-qPCR. Ang II increased MAP1LC3B mRNA levels and protein levels of LC3 I, LC3 II and total LC3 (LC3 I + LC3 II). Cycloheximide, but not actinomycin D, abolished LC3 II and total LC3 increase elicited by Ang II in RASMCs. In A7r5 cells, cycloheximide prevented the Ang II-mediated increase of LC3 I and total LC3, but not LC3 II. Moreover, Ang II increased Bag3 levels, but this increase was not observed upon co-administration with either losartan 1 μM (AT1R antagonist) or Y-27632 10 μM (ROCK inhibitor). These results suggest that Ang II may regulate total LC3 content through transcriptional and translational mechanisms. Moreover, Bag3 is increased in response to Ang II by a AT1R/ROCK signalling pathway. These data provide preliminary evidence suggesting that Ang II may stimulate autophagy in VSMCs by increasing total LC3 content and LC3 processing.Entities:
Keywords: AT1 receptor; Bag3; LC3; ROCK; angiotensin II; autophagy
Mesh:
Substances:
Year: 2022 PMID: 35118791 PMCID: PMC8899170 DOI: 10.1111/jcmm.17215
Source DB: PubMed Journal: J Cell Mol Med ISSN: 1582-1838 Impact factor: 5.310
FIGURE 1Ang II increases LC3 protein levels through transcriptional and translational mechanisms in VSMC. (A) RASMC and A7r5 cells (B) were pre‐treated with cycloheximide (CHX, 100 μM) or actinomycin D (AcD, 5 μM) 1 h before treatment with 100 nM of Ang II for 24 h. Cells were incubated with CQ (30 μM) for the last 4 h of stimulation. LC3 protein content was evaluated by Western blot. (C) RASMC were treated with Ang II for 24 h, and MAP1LC3B mRNA levels were determined by RT‐qPCR. YWHAZ was used as a loading control. Data shown as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 vs control; # p < 0.05, ## p < 0.01, ### p < 0.001 v/s Ang II; $ p < 0.05, vs CQ; & p < 0.05 vs AcD. Statistical analysis was performed using one way ANOVA, followed by Newman–Keuls post‐test, or Student t‐test (n = 3–5)
FIGURE 2Ang II increases Bag3 in A7r5 cells. (A) A7r5 were treated with Ang II 100 nM during 24 h, and Bag3 protein content was assessed by Western blot. (B) Upper panel: A7r5 cells were pre‐treated with losartan 1 μM for 1 h before incubation with Ang II 100 nM for 24 h, and protein content of Bag3 was evaluated by Western blot. Lower panel: A7r5 were pre‐treated with Y‐27632 10 μM, 1 h before stimulation with Ang 100 nM for 24 h. Bag3 protein content was assessed by Western blot. β‐Tubulin served as loading control. Protein levels of all experiments are normalized by β‐tubulin. The data are shown as mean ± SEM, n = 3–5. *p < 0.05, **p < 0.01, ***p < 0.001 vs control; # p < 0.05, ### p < 0.001 vs Ang II. Statistical analysis was performed using Student t‐test, or one way ANOVA, followed by Newman–Keuls post‐test (n = 3–5)